QIAGEN N.V. (QIAGEN), incorporated on April 29, 1996, is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. Its automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight. As of December 31, 2016, the Company provided more than 500 core consumable products (sample and assay kits), as well as instruments that automate the use of these products.
The Company's consumable products include sample technologies to extract and purify molecules of interest from biological samples, and assay technologies that make the information contained in these genomic molecules available for analysis and interpretation. The Company's range of kits support applications, such as plasmid DNA purification, RNA purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after PCR and sequencing, target enrichment, and library preparation for sequencing. Its assay technology solutions contain all the needed reagents to enable customers to target molecules of interest for detection on platforms supporting PCR, NGS or multimodal analysis. Applications include open, general-purpose PCR reagents, as well as kits for the detection of specific viral or bacterial pathogens and parasites in humans and animals, pharmacogenomic testing and genotyping.
The Company's bioinformatics solutions connect laboratory workflows and process amounts of genomic data, reporting relevant insights to enable scientists or clinicians to decide on further action. The Company's bioinformatics solutions include the Ingenuity Variant Analysis, QIAGEN Clinical Insight, CLC Genomics Workbench and GeneGlobe. Ingenuity Variant Analysis is a cloud-based platform, which interprets data from NGS analysis to filter genetic variants and interpret links to diseases. QIAGEN Clinical Insight is a decision support solution, which delivers clinically relevant insights from genomic variants identified in NGS. CLC Genomics Workbench incorporates technology and algorithms to help scientists in analyzing and visualizing data from various NGS platforms. GeneGlobe is a Web-based portal, which enables researchers to search and select gene- and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels and other products.
The Company's instrumentation systems, together with related services and contracts, automate the use of consumables into workflows for a range of laboratory needs. These instruments enable laboratories to perform processes, including nucleic acid sample preparation, assay setup, target detection and interpretation of genomic information. Its automation platforms include QIAsymphony, GeneReader NGS System, Modaplex, QIAcube, EZ1 Advanced XL, QIAxcel, QIAscout, PyroMark, QIAgility and ESEQuant. QIAsymphony is a modular system. Its QIAsymphony RGQ includes three modules: QIAsymphony SP for sample preparation, QIAsymphony AS for assay setup, and its real-time PCR platform Rotor-Gene Q. GeneReader NGS System is a NGS solution with capabilities, such as non-invasive liquid biopsies in addition to tissue samples; sample and library preparation with either QIAcube or QIAsymphony SP as a front-end; Digital NGS technology for control of the analysis and detection of rare mutations, and integration with laboratory information management systems (LIMS). Modaplex is a multimodal automation system integrating amplification, capillary electrophoresis and real-time qPCR (quantitative polymerase chain reaction) quantification of multiple targets in a single reaction. QIAcube robotic workstations provide solutions for automated sample processing with technologies for purification of DNA, RNA and proteins. EZ1 Advanced XL performs automated nucleic acid purification for various sample types in molecular diagnostics, human identity testing, forensics, biomedical research and gene expression analysis.
The Company competes with Promega Corp., Merck KGaA, Macherey-Nagel GmbH, Thermo Fisher, Sigma-Aldrich Corp., Roche Diagnostics GmbH, Abbott, Siemens, Cepheid and Hologic.
Hulsterweg 82
The company trades on NASDAQ exchange. The company headquarter is located in Netherlands. The company was established in the 1986.| Ticker | QGEN |
| Long Name | Qiagen N.V. |
| Short Name | Qiagen |